How does vyndaqel stabilize transthyretin?

How does VYNDaqel (tafamidis) stabilize transthyretin?

VYNDaqel contains tafamidis, a small molecule designed to bind to transthyretin (TTR) and stabilize it. By stabilizing the native (normal) TTR tetramer, tafamidis makes TTR less likely to dissociate into misfolded forms that can aggregate in tissues and drive transthyretin amyloidosis (ATTR) disease processes. [1]

What does “stabilize” mean for TTR at the protein level?

Transthyretin is a tetrameric protein. In ATTR, the tetramer can break apart (dissociate), and the resulting misfolded protein species can form amyloid fibrils. Tafamidis binds TTR in a way that stabilizes the tetrameric structure, reducing that dissociation step and the downstream formation of amyloid deposits. [1]

Does VYNDaqel treat both ATTR cardiomyopathy and ATTR polyneuropathy the same way?

Yes. The therapeutic effect of tafamidis across indications comes from the same mechanism: stabilizing transthyretin to reduce misfolding and amyloid formation. Clinical labeling distinguishes disease settings (for example, cardiomyopathy vs polyneuropathy), but the underlying drug-target mechanism is stabilization of TTR. [1]

Source

[1] Drug label/Drug information for VYNDaqel (tafamidis) via DrugPatentWatch.com: https://www.drugpatentwatch.com/